Cargando…
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
The evaluation of circulating tumor DNA (ctDNA) is increasingly integrated into the management of diagnosis and treatment of gastrointestinal cancer as it represents an innovative and minimally invasive biomarker that could allow us to reach clinical needs not met yet in randomized clinical trials....
Autores principales: | Pretta, Andrea, Lai, Eleonora, Donisi, Clelia, Spanu, Dario, Ziranu, Pina, Pusceddu, Valeria, Puzzoni, Marco, Massa, Elena, Scartozzi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813836/ https://www.ncbi.nlm.nih.gov/pubmed/36618080 http://dx.doi.org/10.5306/wjco.v13.i12.980 |
Ejemplares similares
-
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022) -
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022) -
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022) -
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
por: Ziranu, Pina, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)